CA-PERSONALIS,-INC.
17.5.2021 14:03:58 CEST | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Biomarkers Week Online 2021.
The presentation , titled “ImmunoID NeXT Platform® for comprehensive tumor immunogenomics and advanced biomarker discovery,” will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT ™. Erin Newburn, MS, PhD, will present for Personalis. Dr. Newburn will provide an overview of the platform, which combines highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics to provide a multidimensional view of the tumor and the tumor microenvironment (TME) from a single sample preparation. Dr. Newburn will review a case study in a cohort of 51 late-stage melanoma patients that demonstrates how the integration of neoantigen burden, HLA LOH, and Antigen Presentation Machinery (APM) mutational data formed a composite biomarker that more accurately predicted response to checkpoint blockade than other markers. Additionally, Dr. Newburn will highlight our NeXT Liquid Biopsy™, an exome-wide liquid biopsy approach combined with ImmunoID NeXT, to further explore critical areas of tumor biology.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The ImmunoID NeXT Platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Personalis is a co-sponsor of Biomarkers Week and will have representatives available to answer questions about the company’s cancer immunogenomics capabilities.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency, and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue and matched blood sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, Personalis’ business opportunities, leadership, plans, vision or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005432/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify's Q2 Global Air Travel Fraud Report Finds Fraud Pressure Intensifying Across Middle East and Africa15.7.2026 13:00:00 CEST | Press release
Analysis of nearly 133 million airline booking transactions finds bookings departing from Cairo carried the world's highest fraud rate this quarter, while departure cities across the United States and Australia posted among the lowest fraud rates Accertify, a leading fraud decisioning provider whose Predictive Yes Platform helps merchants say yes to more good customers, more revenue, and more growth, today announced the release of its Global Air Travel Fraud Report: Q2 2026, a quarterly analysis examining how fraud pressure varies across global airline markets based on departure city at time of booking. Based on analysis of 132.9 million airline booking transactions processed between April and June 2026, the report evaluates prevented fraud rates across 537 departure cities that each processed at least 10,000 transactions during the quarter, providing airlines with a data-driven view of where Accertify's Predictive Yes platform intervened most frequently at booking. The Q2 findings rev
Forrester’s 2027 Budget Planning Guides: After A Year Of Caution, Business And Tech Leaders Are Ready To Invest Again15.7.2026 11:00:00 CEST | Press release
While leaders are betting on growth, in the age of AI, spending more is no longer enough According to Forrester’s (Nasdaq: FORR) 2027 Budget Planning Guides, business and technology leaders are approaching 2027 with renewed confidence as they increasingly accept volatility as a permanent feature of the business environment. After a year of more cautious spending, more than 80% of leaders expect their budgets to increase over the next 12 months, with as many as one-quarter anticipating growth of 10% or more. But planning in the age of AI demands more than bigger budgets: Increasing investment without modernizing operating models, strengthening data foundations, and improving AI readiness will only accelerate fragmented data, duplicated work, and technical debt. To realize AI’s full potential, leaders must rethink their strategies and prioritize investments in operational foundations, governance, and experimentation that drive tangible outcomes. This year, optimism is widespread across f
Post-Quantum’s Algorithm - Classic McEliece - Achieves Global ISO Standardization to Protect the World From Quantum Cyber Attack15.7.2026 10:00:00 CEST | Press release
Ultra-secure encryption algorithm added to ISO standard for Asymmetric Ciphers Classic McEliece is first PQC algorithm to achieve global standardization Organisations in 177 ISO member states can now adopt Classic McEliece to remain secure from attack by both classical and quantum computers Governments including Germany and the Netherlands already recommend the highly secure Classic McEliece algorithm due to its unmatched security credentials It’s proven that today’s encryption is vulnerable to attack by a sufficiently mature quantum computer running Shor’s algorithm - a catastrophic event commonly known as Q-Day. Even before such a cryptographically relevant quantum computer emerges it is known that adversaries are stealing encrypted data now, which can be decrypted later - also known as Harvest Now, Decrypt Later (HNDL). Google’s recent use of Artificial Intelligence (AI) to optimise Shor’s algorithm reduces the number of physical qubits required to break today’s encryption, therefor
Thredd Joins The Visa Agentic Ready Programme, Bringing Agent Network Readiness To Issuers Across Europe, Starting With Zilch15.7.2026 09:00:00 CEST | Press release
Thredd, the AI-first issuer processing platform, today announced it has joined the Visa Agentic Ready programme, enabling issuers across Europe to participate in agent-initiated payments without rebuilding their payments infrastructure. Consumer payments platform Zilch will be among the first issuers on the platform to enable agent-initiated payments for its cardholders. As a processor and enabler, Thredd sits at the trust layer of the payments ecosystem. By joining the programme, Thredd is ready to support Visa and its clients as the market moves into agentic commerce. Agentic commerce introduces a new type of payment initiator: An AI agent acting on a cardholder's behalf. The core payments principles do not change. Cardholder permission, issuer approval, authentication and fraud monitoring all still apply. What changes is how trust is established and enforced at the point an agent transacts. Taking a Zilch customer as an example, a cardholder might ask an AI agent to find a product w
Surgerii Robotics Announces First European Installation of the SHURUI® Single-Port Surgical System at Vall d'Hebron University Hospital15.7.2026 09:00:00 CEST | Press release
Surgerii Robotics today announced the first European installation of its SHURUI Single-Port (SP) Surgical System at Vall d'Hebron University Hospital in Barcelona, Spain, one of Europe's leading academic medical centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713209503/en/ The first pediatric procedure performed with the SHURUI SP system was a nephroureterectomy on a twelve-year-old boy whose kidney and ureter had become infected and non-functional due to multiple stones. The SHURUI SP system is CE-marked for adult and pediatric use, making it the only CE-marked single-port robotic surgical system currently indicated for pediatric procedures in Europe. The installation marks an important milestone in the international expansion of Surgerii Robotics and the introduction of the technology into a major European reference center. As part of this collaboration, Vall d'Hebron University Hospital has become the first hos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom